SEFRIA™ Fentanyl Assay

The SEFRIA™ Fentanyl Assay will be the first of a new range of cutting-edge enzyme immunoassays, utilizing both synthetic and recombinant enzyme fragments of beta-galactosidase for superb sensitivity and vastly improved analysis.

Due to its extremely low cut-off, this assay is especially suited for the monitoring of transdermal patches and oral transmucosal Fentanyl citrate lollipops. The SEFRIA™ Fentanyl Assay is a strong screening tool to monitor compliance on the one hand, and for the detection of Fentanyl abuse on the other.

Assay Characteristics

  • Cut-off as low as 1 ng/mL leads to fewer false-negative results
  • Excellent separation between controls and calibrators
  • No cross-reactivity with norfentanyl
  • Liquid-stable, ready-to-use reagents, calibrators, and controls
  • Application protocols for all major clinical chemistry analyzers
  • Packaging tailored to your laboratory’s unique needs
  • Use of synthetic material to enhance stability of calibrators and controls, and to decrease risk of contamination
Specialty Diagnostix Sefria Fentanyl Assay

Background

First synthesized in the late 1950s, Fentanyl was found to be significantly more potent than commonly used opioids, such as morphine or pethidine. It is a potent synthetic opioid analgesic which has been introduced as a widespread palliative, especially in form of transdermal patches and other quick-acting prescription forms in chronic pain management and for cancer patients.

As of the mid-1970s, Fentanyl has also been used as a recreational drug. Apparently, its effects are similar to that of heroin, with stronger sedative results. Fentanyl is also a very short-acting drug so users become addicted quite rapidly. On the illicit markets, Fentanyl is sold in all available forms. Users may cut up patches and eat them or take the gel inside the patch to smoke it.